Drawing for LEAFBIO

USPTO serial 85710504

LEAFBIO

Reviewed by CopyMark Law Group

Reg. 4969019Status 702Renewal
Filing date
Status date
Registration date
May 31, 2016
Examiner
WILKE, JOHN
Law office
TMEG LAW OFFICE 104

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Status 702: Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use.

Need help with LEAFBIO?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,097*

Plus Government fees of $2,550

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Paul Nardulli

Paul Nardulli OPTIMA LAW GROUP, APC4275 Executive Square, Suite 200La Jolla, CA 92037UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
001Diagnostic reagents for scientific or research use; [ Diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents to monitor toxicity of drugs; ] Diagnostic reagents for clinical or medical laboratory use; [ Diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; ] Diagnostic reagents for scientific or research use; Laboratory chemicals, namely, an antibody reagent used for the detection of antigens in cell and tissue analysis for in vitro diagnostic use; [ Reagent for chemical analysis; ] Reagents for research purposes; Reagents for scientific or medical research use; [ Reagents for testing the sterility of pharmaceuticals and injectable solutions; ] Reagents for use in scientific apparatus for chemical or biological analysis; Reagents for use in biodefenseACTIVEJan 1, 2013
005Pharmaceutical products for use in the treatment and prevention of [ cardiovascular diseases and disorders, central nervous system and neurological diseases and disorders, urological diseases and disorders, ] viral and infectious diseases, [ cancer, gastrointestinal diseases and disorders, musculoskeletal diseases and disorders, migraines and headaches, pain, hypertension, ] inflammation and inflammatory diseases and disorders, [ metabolic diseases and disorders, ] respiratory and infectious diseases and disorders, immunological, bacterial, viral and fungal diseases and disorders, [ psychiatric diseases and disorders, asthma, allergies, diabetes, obesity, stroke, erectile and sexual dysfunction, ] sexually transmitted infections including, but not limited to, HIV, HPV, and herpes [, and hemolytic diseases and disorders; Pharmaceutical preparations, namely, cholesterol preparations, osteoporosis preparations, oncological preparations, dermatological preparations, urological preparations, ophthalmologic preparations, tissue and skin repair preparations and gynecological preparations ] ; Pharmaceuticals, namely, anti-infectives; [ Diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; Medical diagnostic reagents; Medical diagnostic reagents and assays for testing of body fluids, including for microorganisms; Drug delivery agents consisting of compounds that facility delivery of a wide range of pharmaceuticals; ] Antibacterial pharmaceuticals; [ Cardiovascular pharmaceuticals; ] Contraceptive foams, sponges, preparations; [ Oral contraceptives; ] Pharmaceutical products for use in biodefenseACTIVEJan 1, 2013
042Pharmaceutical research and development; research and development of pharmaceutical preparations for the treatment and prevention of [ cardiovascular diseases and disorders, central nervous system and neurological diseases and disorders, ] viral and infectious diseases, [ cancer, urological diseases and disorders, ] gastrointestinal diseases and disorders, [ musculoskeletal diseases and disorders, migraines and headaches, pain, hypertension, ] inflammation and inflammatory diseases and disorders, [ metabolic diseases and disorders, ] respiratory and infectious diseases and disorders, immunological, bacterial, viral and fungal diseases and disorders, [ psychiatric diseases and disorders, asthma, allergies, diabetes, obesity, stroke, erectile and sexual dysfunction, ] sexually transmitted infections including, but not limited to, HIV, HPV, and herpes [ and hemolytic diseases and disorders; research and development of pharmaceutical preparations, namely, cholesterol preparations, osteoporosis preparations, oncological preparations, dermatological preparations, urological preparations, ophthalmologic preparations, tissue and skin repair preparations and gynecological preparations ] ; research and development of drug delivery devices; medical and scientific research, namely, conducting clinical trials; Consulting services in the fields of biotechnology, pharmaceutical research and development, [ laboratory testing, diagnostics, ] and pharmacogenetics; Development of pharmaceutical preparations and medicines; Pharmaceutical drug development; Pharmaceutical research and development services; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; [ Providing reagent sample testing and diagnostic services for others in the fields of science and research related thereto; ] Pharmaceutical research and development in relation to biodefenseACTIVEJan 1, 2013

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jun 1, 2025REM2COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED—
Nov 30, 2022NA85NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED—
Nov 30, 2022C15AREGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.—
Nov 17, 2022APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
May 12, 2022E815TEAS SECTION 8 & 15 RECEIVED—
May 31, 2016R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Apr 26, 2016SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE MAILED—
Apr 23, 2016CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED—
Apr 16, 2016SUPCSTATEMENT OF USE PROCESSING COMPLETE—
Mar 17, 2016IUAFUSE AMENDMENT FILED—
Mar 17, 2016EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Sep 29, 2015EXRANOTICE OF APPROVAL OF EXTENSION REQUEST MAILED—
Sep 27, 2015EX5GSOU EXTENSION 5 GRANTED—
Sep 9, 2015EXT5SOU EXTENSION 5 FILED—
Sep 9, 2015EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 4, 2015EXRANOTICE OF APPROVAL OF EXTENSION REQUEST MAILED—
Apr 3, 2015EX4GSOU EXTENSION 4 GRANTED—
Mar 20, 2015EXT4SOU EXTENSION 4 FILED—
Mar 20, 2015EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Oct 2, 2014EXRANOTICE OF APPROVAL OF EXTENSION REQUEST MAILED—
Oct 1, 2014EX3GSOU EXTENSION 3 GRANTED—
Sep 19, 2014EXT3SOU EXTENSION 3 FILED—
Sep 19, 2014EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jun 3, 2014TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Apr 18, 2014EXRANOTICE OF APPROVAL OF EXTENSION REQUEST MAILED—
Apr 17, 2014EX2GSOU EXTENSION 2 GRANTED—
Apr 14, 2014AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Mar 20, 2014EXT2SOU EXTENSION 2 FILED—
Mar 20, 2014EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Sep 26, 2013EXRANOTICE OF APPROVAL OF EXTENSION REQUEST MAILED—
Sep 24, 2013EX1GSOU EXTENSION 1 GRANTED—
Sep 24, 2013EXT1SOU EXTENSION 1 FILED—
Sep 24, 2013EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Mar 26, 2013NOAMNOA MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Jan 29, 2013PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jan 9, 2013NPUBNOTICE OF PUBLICATION—
Dec 17, 2012CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Dec 15, 2012DOCKASSIGNED TO EXAMINER—
Aug 31, 2012MPMKNOTICE OF PSEUDO MARK MAILED—
Aug 30, 2012NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 25, 2012NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance